Lamotrigine toxicity secondary to sertraline

  title={Lamotrigine toxicity secondary to sertraline},
  author={Kenneth R. Kaufman and Robert H. Gerner},

Tables from this paper

Delirium Secondary to Lamotrigine Toxicity.
Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamOTrigine toxicity, and patients may experience adverse medication effects despite lamotigine levels that are normally considered to be in the therapeutic range.
Clinical Pharmacokinetics of Sertraline
Sertraline is a naphthalenamine derivative with the predominant pharmacological action of inhibiting presynaptic reuptake of serotonin from the synaptic cleft that is well tolerated in therapeutic dosages and relatively safe in overdosage.
Postmortem investigation of lamotrigine concentrations.
It is highlighted the importance of monitoring lamotrigine concentrations in cases co-medicated, particularly with valproic acid, as co-administration has been shown in the literature to lead to elevated lamotigine concentrations and a reduction in lamotigrine dose has been recommended.
Suivi thérapeutique pharmacologique de la lamotrigine.
Lamotrigine is a second generation anticonvulsant drug available in France and used in type I bipolar disorders and except legal notices, in the treatment of neuropathic pains and the correlation concentration-toxicity is better argued.
Drug Interactions Between Lamotrigine and Psychoactive Drugs: Evidence From a Therapeutic Drug Monitoring Service
Concerning pharmacokinetic drug interactions, it is concluded that lamotrigine can be safely combined with most psychotropic drugs.
The Clinical Pharmacokinetics of the New Antiepileptic Drugs
Summary: Because pharmacokinetics is a major determinant of the magnitude and duration of pharmacologic response, understanding the kinetic properties of the new antiepileptic drugs (AEDs) is
Bioavailability File: Lamotrigine
  • Biology, Chemistry
LTG is a phenyltriazine class anticonvulsant that shows efficacy against partial and generalized epilepsies and its physicochemical properties, analytical methods, pharmacokinetics, bioavailability and pharmacology are discussed in this review.
Safety and Tolerability of Lamotrigine: Results From 12 Placebo-Controlled Clinical Trials and Clinical Implications
The data regarding the safety and tolerability of lamotrigine in the treatment of bipolar disorder is gathered from 12 placebo-controlled trials, regardless of publication status, that were sponsored by GlaxoSmithKline.
Metabolism and Excretion of Mood Stabilizers and New Anticonvulsants
Several of the newer anticonvulsants lack the problematic drug-drug interactions seen with older agents, and some may even (based on their mechanisms of action and preliminary preclinical and clinical data) ultimately prove to have novel psychotropic effects.
Safety and Efficacy of Lamotrigine in Older Adults with Epilepsy and Co-Morbid Depressive Symptoms:
The main advantage of lamotrigine for the treatment of this indication in the elderly lies in its favorable and predictive adverse event profile and drug-drug interactions in comparison to other AEDs.


Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans
The pharmacokinetics of lamotrigine, a new anticonvulsant, were studied in three studies in normal volunteers, suggesting the absence of autoinduction of metabolism.
Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.
A considerable improvement of the patient's condition was achieved several days after the beginning of lamotrigine co-administration, and lasted over the total follow-up period of more than one year.
The New Anticonvulsant Drugs
Vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage with increments of 0.5 g/day, and gabapentin, a very safe add-on medication, is a welcome addition for the treatment of refractary partial epilepsy.
Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog.
The whole brain concentration of sertraline in the rat is more than 40-fold higher than that in plasma, and the volume of distribution is about 25 liters/kg in the rats and dog.
Sodium valproate acutely inhibits lamotrigine metabolism.
Concomitant administration of sodium valproate (VPA) reduced lamotrigine (LTG) total clearance by approximately 21% and increased elimination half-life and AUC and the most probable explanation is hepatic competition between VPA and LTG for glucuronidation.
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
It is suggested that compounds with SSRI activity are likely to interact with human CYP2D6 in vivo with the potential of causing drug interactions.
New antidepressants: use in high-risk patients.
Evidence on the safety and efficacy of new antidepressants in high-risk patients is reviewed and data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs) and the new reversible inhibitor of monoamine oxidase-A moclobemide.
Fatal course of toxic epidermal necrolysis under treatment with lamotrigine.
We report on the first fatal course of toxic epidermal necrolysis (Lyell's disease) occurring under treatment with lamotrigine, following the development of a skin rash caused by carbamazepine.
Current Psychiatric Therapy II
The foundations of Disorders and Treatment: Structural Foundations of Illness and Treatment, and the Implications of Criteria Changes for DSM IV Schizophrenia.